Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
PBA-0111 in Squamous Cell Carcinoma of Head and Neck: NCT06700070 Clinical Landscape Report 2026
15 October 2026
NCT06700070 clinical landscape for Squamous Cell Carcinoma of Head and Neck: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
Trilaciclib Dihydrochloride in Bone marrow depression: NCT06699472 Clinical Landscape Report 2026
15 October 2026
NCT06699472 clinical landscape for Bone marrow depression: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cemiplimab-RWLC in Locally Advanced Clear Cell Renal Cell Carcinoma: NCT06699602 Clinical Landscape Report 2026
15 October 2026
NCT06699602 clinical landscape for Locally Advanced Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Anlotinib Dihydrochloride in Locally Advanced Soft Tissue Sarcoma: NCT06699576 Clinical Landscape Report 2026
15 October 2026
NCT06699576 clinical landscape for Locally Advanced Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Decitabine in Diffuse Large B-Cell Lymphoma: NCT06701357 Clinical Landscape Report 2026
15 October 2026
NCT06701357 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GF-CART01 in High grade B-cell lymphoma: NCT06703892 Clinical Landscape Report 2026
15 October 2026
NCT06703892 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Autologus rapamycin resistant T-cell therapy (Rapa Therapeutics) in Malignant melanoma, metastatic: NCT06708455 Clinical Landscape Report 2026
15 October 2026
NCT06708455 clinical landscape for Malignant melanoma, metastatic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HX-009 in Advanced Bile Duct Carcinoma: NCT06708663 Clinical Landscape Report 2026
15 October 2026
NCT06708663 clinical landscape for Advanced Bile Duct Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IDE275 in Rectal Cancer: NCT06710847 Clinical Landscape Report 2026
15 October 2026
NCT06710847 clinical landscape for Rectal Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nolgileucel in Uveal Melanoma: NCT06703398 Clinical Landscape Report 2026
15 October 2026
NCT06703398 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Advanced Renal Cell Carcinoma: NCT06708949 Clinical Landscape Report 2026
15 October 2026
NCT06708949 clinical landscape for Advanced Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-CD19 IL-10/IL15 CAR-NK Cells(The Second Affiliated Hospital Zhejiang University) in B-Cell Lymphoma: NCT06707259 Clinical Landscape Report 2026
15 October 2026
NCT06707259 clinical landscape for B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.